Imatinib mesylate for platelet-derived growth factor receptor-beta positive Erdheim-Chester histiocytosis

Blood

Volumn 111, Issue 11, 2008, Pages 5413-5415

  Haroche, Julien ^a   Amoura, Zahir ^b   Charlotte, Frédéric ^b   Salvatierra, Juan ^b   Wechsler, Bertrand ^b   Graux, Carlos ^b   Brousse, Nicole ^b   Piette, Jean Charles ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; IMATINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

CARDIOVASCULAR DISEASE; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; DRUG DOSE INCREASE; DRUG EFFICACY; ERDHEIM CHESTER DISEASE; HISTIOCYTOSIS X; HUMAN; LETTER; PRIORITY JOURNAL; PROGNOSIS; ROSAI DORFMAN DISEASE; TREATMENT RESPONSE; ADULT; FEMALE; MALE; METABOLISM; MIDDLE AGED;

ADULT; ERDHEIM-CHESTER DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA;

EID: 45949102275     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-03-148304     Document Type: Letter

References (10)

1. Chester W. Über lipoidgranulomatose. Virchows Arch Pathol Anat. 1930;279:561-602.
2. Veyssier-Belot C, Cacoub P. Caparros-Lefebvre D, et al. Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases. Medicine. 1996;75:157-169.
3. Braiteh F, Boxrud G, Esmaeli B, Kurzrock R. Successful treatment of Erdheim-Chester disease, a non-Langerhans cell histiocytosis, with interferon-alpha. Blood. 2005;106:2992-2994.
4. Haroche J. Amoura Z, Dion E, et al. Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review. Medicine. 2004;83:371-392.
5. Haroche J, Amoura Z, Trad SG, et al. Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients. Arthritis Rheum. 2006;54:3330-3336.
6. Montella L, Insabato L, Palmieri G. Imatinib mesylate for cerebral Langerhans'- cell histiocytosis. N Engl J Med. 2004;351:1034-1035.
7. Utikal J, Ugurel S, Kurzen H, et al. Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses. Arch Dermatol. 2007;143:736-740.
8. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295:139-145.
9. ApperleyJF, Gardembas M, Melo JV. et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002;347:481-487.
10. Pardanani A, Tefferi A. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood. 2004;104:1931-1939.